March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
2-deoxy-D-glucose (2-DG): In vivo Evaluation of Anti-angiogenic Impact on Retinoblastoma Tumor Vasculature
Author Affiliations & Notes
  • Nikesh N. Shah
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Samuel Houston
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Yolanda Piña
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Timothy G. Murray
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Christina L. Decatur
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Jaime Merchan
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Theodore Lampidis
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Footnotes
    Commercial Relationships  Nikesh N. Shah, None; Samuel Houston, None; Yolanda Piña, None; Timothy G. Murray, None; Christina L. Decatur, None; Jaime Merchan, None; Theodore Lampidis, None
  • Footnotes
    Support  R01 EY013629, R01 EY12651, and P30 EY014801; and by an unrestricted grant to the University of Miami from Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1873. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nikesh N. Shah, Samuel Houston, Yolanda Piña, Timothy G. Murray, Christina L. Decatur, Jaime Merchan, Theodore Lampidis; 2-deoxy-D-glucose (2-DG): In vivo Evaluation of Anti-angiogenic Impact on Retinoblastoma Tumor Vasculature. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1873.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The aim of the current study is to assess the impact of the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) on angiogenesis in advanced retinoblastoma tumors.

Methods: : The study protocol was approved by the University of Miami Institutional Animal Care and Use Review Board Committee and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. LHBETATAG mice received injections at 16 weeks of age (advanced tumors) of either saline or 2-DG. 2-DG (500 mg/kg) was administered through intraperitoneal injection, 3 times a week for 5 weeks (n = 5). Saline was administered the same way (n = 4). Eyes were enucleated at 21 weeks and tumor sections were analyzed for angiogenesis. The densities of new, mature, and total blood vessels were measured.

Results: : 2-DG significantly reduced the total density of new blood vessels (endoglin) in tumors by 44% compared to saline controls (P < 0.001), but did not affect the densities of both mature (α-sma) and total vasculature (lectin) when compared with controls (P > 0.05).

Conclusions: : Treatment with 2-DG was shown to reduce the density of neovessels, demonstrating an antiangiogenic effect in vivo. As a result, 2-DG may represent a new strategy for angiogenesis inhibition in vivo, therefore, may have significant potential as alternative therapies for treating children withretinoblastoma.

Keywords: retinoblastoma • transgenics/knock-outs • blood supply 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×